IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Blepharospasm

Main Inclusion Criteria: * Male or female pretreated outpatients between ages 18 and 80 years (inclusive) * A clinical diagnosis of bilateral blepharospasm (BEB) characterized by spontaneous, spasmodic, intermittent or persistent involuntary contractions of the orbicular oculi muscles * A need for injection of Botulinum toxin (defined by a Jankovic Rating Scale (JRS) severity subscore \>= 2) * On a stable dose of other medications (if any) used for focal dystonia treatment (e.g. anticholinergics and benzodiazepines) for at least 3 months prior to and expected throughout the Main Period * Source documentation of the last two consecutive injection sessions with BOTOX® and a stable satisfactory therapeutic response directly prior to trial entry * At least 10 weeks must have been passed between the last injection with BOTOX® for BEB and Baseline Main Exclusion Criteria: * Atypical variant of BEB caused by inhibition of levator palpebrae muscle * Myotomy or denervation surgery in the affected muscles (e.g. peripheral denervation and/or spinal cord stimulation) * The previous two injections with BOTOX® with more than 50 Units per eye * Hypersensitivity to human serum albumin, sucrose, or Botulinum toxin A * Neuroleptic induced blepharospasm * Diagnosis of myasthenia gravis, Lambert-Eaton syndrome, amyotrophic lateral sclerosis, or any other significant neuromuscular disease which might interfere with the trial * Treatment with Botulinum toxins for any indication other than BEB within 4 months prior to Baseline and during the trial